Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H22O11 |
Molecular Weight | 414.3607 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12OC(=O)C3=CO[C@@H](O[C@]4([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@]([H])(C(COC(C)=O)=C1)[C@]23[H]
InChI
InChIKey=IBIPGYWNOBGEMH-DILZHRMZSA-N
InChI=1S/C18H22O11/c1-6(20)25-4-7-2-9-12-8(16(24)27-9)5-26-17(11(7)12)29-18-15(23)14(22)13(21)10(3-19)28-18/h2,5,9-15,17-19,21-23H,3-4H2,1H3/t9-,10+,11+,12-,13+,14-,15+,17-,18-/m0/s1
Molecular Formula | C18H22O11 |
Molecular Weight | 414.3607 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26710167Curator's Comment: Description was created based on several sources, including
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26710167
Curator's Comment: Description was created based on several sources, including
Asperuloside, an iridoid glycoside found in Herba Paederiae, is a component from traditional Chinese herbal medicine. Asperuloside is extracted from many traditional Chinese medicinal plants, including Herba Paederiae, Asperula odorata, Goldhair Hedyotis Herb and Hedyotis diffusa. It has been proved that there are many kinds of pharmacological effects such as anti-tumor and anti-obesity activities. Asperuloside can significantly downregulate tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β, and IL-6 levels in vitro and in vivo, and treatment with asperuloside significantly reduced the lung wet-to-dry weight, histological alterations and myeloperoxidase activity in a murine model of LPS-induced acute lung injury (ALI). Asperuloside exerts its anti-inflammatory effect in correlation with inhibition of a pro-inflammatory mediator through suppressing nuclear factor kappa-B (NF-κB) nuclear translocation and MAPK phosphorylation. Asperuloside can be a potential treatment for ALI and can be used as a clinical anti-infective drug.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0000165 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26710167 |
|||
Target ID: GO:0006629 |
|||
Target ID: Phosphatidylinositol-3-kinase Sources: https://www.ncbi.nlm.nih.gov/pubmed/7872663 |
2.0 µM [IC50] | ||
Target ID: CHEMBL4984 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16508180 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26710167
20, 40, and 80 mg/kg, given intraperitoneally
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26710167
Asperuloside ((20–80 mg/L) significantly downregulates tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β, and IL-6 levels in RAW 264.7 cells
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:32:51 GMT 2023
by
admin
on
Fri Dec 15 18:32:51 GMT 2023
|
Record UNII |
V3CFI02X39
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
238-137-5
Created by
admin on Fri Dec 15 18:32:51 GMT 2023 , Edited by admin on Fri Dec 15 18:32:51 GMT 2023
|
PRIMARY | |||
|
DTXSID70878339
Created by
admin on Fri Dec 15 18:32:51 GMT 2023 , Edited by admin on Fri Dec 15 18:32:51 GMT 2023
|
PRIMARY | |||
|
84298
Created by
admin on Fri Dec 15 18:32:51 GMT 2023 , Edited by admin on Fri Dec 15 18:32:51 GMT 2023
|
PRIMARY | |||
|
14259-45-1
Created by
admin on Fri Dec 15 18:32:51 GMT 2023 , Edited by admin on Fri Dec 15 18:32:51 GMT 2023
|
PRIMARY | |||
|
31760
Created by
admin on Fri Dec 15 18:32:51 GMT 2023 , Edited by admin on Fri Dec 15 18:32:51 GMT 2023
|
PRIMARY | |||
|
V3CFI02X39
Created by
admin on Fri Dec 15 18:32:51 GMT 2023 , Edited by admin on Fri Dec 15 18:32:51 GMT 2023
|
PRIMARY | |||
|
m2104
Created by
admin on Fri Dec 15 18:32:51 GMT 2023 , Edited by admin on Fri Dec 15 18:32:51 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |